FMR LLC raised its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 283.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,393 shares of the biopharmaceutical company's stock after purchasing an additional 33,546 shares during the quarter. FMR LLC owned about 0.08% of Agios Pharmaceuticals worth $2,017,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its holdings in shares of Agios Pharmaceuticals by 4.1% in the third quarter. The Manufacturers Life Insurance Company now owns 143,431 shares of the biopharmaceutical company's stock valued at $6,373,000 after purchasing an additional 5,587 shares during the period. Loomis Sayles & Co. L P boosted its position in Agios Pharmaceuticals by 36.4% in the third quarter. Loomis Sayles & Co. L P now owns 612,366 shares of the biopharmaceutical company's stock valued at $27,208,000 after buying an additional 163,503 shares during the last quarter. Fisher Asset Management LLC increased its holdings in Agios Pharmaceuticals by 20.5% in the 3rd quarter. Fisher Asset Management LLC now owns 855,328 shares of the biopharmaceutical company's stock worth $38,002,000 after buying an additional 145,416 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Agios Pharmaceuticals by 1.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 465,620 shares of the biopharmaceutical company's stock worth $20,687,000 after buying an additional 8,093 shares during the period. Finally, Intech Investment Management LLC purchased a new position in Agios Pharmaceuticals during the 3rd quarter worth approximately $892,000.
Agios Pharmaceuticals Price Performance
AGIO stock traded up $0.80 during mid-day trading on Friday, reaching $38.97. 1,351,107 shares of the company's stock were exchanged, compared to its average volume of 717,473. Agios Pharmaceuticals, Inc. has a 12-month low of $20.96 and a 12-month high of $62.58. The stock's 50 day moving average is $50.02 and its 200 day moving average is $46.70. The company has a market cap of $2.22 billion, a price-to-earnings ratio of 3.43 and a beta of 0.80.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on AGIO shares. Leerink Partners lowered shares of Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and cut their price objective for the stock from $60.00 to $56.00 in a research note on Friday, September 27th. Raymond James reaffirmed an "outperform" rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Cantor Fitzgerald reissued an "overweight" rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Scotiabank raised their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a report on Monday, December 9th. Finally, StockNews.com raised Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, November 9th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $56.33.
Check Out Our Latest Analysis on Agios Pharmaceuticals
Insider Activity
In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the business's stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.93% of the company's stock.
Agios Pharmaceuticals Company Profile
(
Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Recommended Stories
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.